D
NA mismatch repair (MMR) contributes to the preservation of genomic stability by correcting replication errors that escaped proofreading at the replication fork (1) . Because such errors are confined to newly synthesized DNA, the exonucleasemediated removal of the replication error is directed to the daughter strand, and DNA is resynthesized by using the parental strand as template. It turns out that certain mismatched base pairs, where one of the partners is actually a damaged DNA base, can also be bound by the MMR recognition complexes MutS␣ and MutL␣ (2) . One such damaged DNA base is O 6 -methylguanine (O 6 MeG), and the binding of MutS␣ and MutL␣ to an O 6 MeG-containing DNA base pair has been shown to be a strong trigger for apoptosis (3) (4) (5) (6) .
O 6 MeG DNA lesions are induced by S N 1-alkylating agents, such as N-methyl-NЈ-nitrosourea (MNU) and N-methyl-NЈ-nitro-Nnitrosoguanidine (MNNG), both of which are prototypical of several drugs used for cancer chemotherapy (7) . It is important to note that another chemotherapeutic agent, 6-thioguanine, produces damaged DNA bases that also signal apoptosis in a MutS␣-and MutL␣-dependent way. Indeed, many tumors deficient in MutS␣ or MutL␣ can become resistant to 6-thioguanine and alkylation chemotherapy, presumably because MMR is unable to signal apoptosis from therapy-induced DNA base damage.
O 6 MeG DNA methyltransferase (Mgmt) demethylates O 6 MeG to G in a suicide reaction that transfers the O 6 -methyl group onto the Mgmt active-site cysteine (8) . In the absence of adequate Mgmt, unrepaired O 6 MeGs pair with T during DNA replication. If the O 6 MeG:T mismatch escapes recognition by MutS␣ or MutL␣, it generates G:C to A:T transitions at every subsequent replication with little or no cell death. However, recognition of the O 6 MeG:T mismatch by MutS␣-and MutL␣ somehow triggers apoptosis, thus preventing the accumulation of mutant cells in the population.
Mgmt-null mice have no detectable Mgmt activity in any tissue (9) (10) (11) and are hypersensitive to S N 1-alkylating agents (9, 11, 12) . The most alkylation-sensitive Mgmt-null tissues are fast proliferating tissues, especially the bone marrow (BM) (9, 11, 12) . A mouse model combining Mgmt and MutL␣ deficiencies was generated (13) ; the Mgmt Ϫ/Ϫ Mlh1 Ϫ/Ϫ mice are extremely alkylation-resistant compared with Mgmt-null mice, and their resistance is comparable with that of wild-type mice. However, Mgmt Ϫ/Ϫ Mlh1 Ϫ/Ϫ mice are very sensitive to alkylation-induced lymphoma, suggesting that when O 6 MeG lesions escape MMR processing, allowing the cell to escape death, the lesions go on to generate mutations that lead to cancer (13) ; these studies underscore the importance that apoptosis signaled by MMR proteins plays in tumor suppression.
The mechanism by which MMR processing at O 6 MeG and other DNA lesions triggers apoptosis has become quite controversial. The original model invokes excision and resynthesis of a DNA segment opposite O 6 MeG to remove the thymine that paired with O 6 MeG during replication (14) (15) (16) (17) . However, thymine is highly likely to be reinserted opposite O 6 MeG, leading to repeated binding of MutS␣-and MutL␣ and recurrent cycles of excision and resynthesis. It was suggested that a combination of the single-stranded DNA breaks and gaps that thus persist in the genome and/or the double-stranded DNA breaks that would form at the next round of replication are what ultimately signals apoptosis. More recently, several lines of evidence support an alternative model wherein simple binding of MutS␣ and MutL␣ to the O 6 MeG:T mismatch leads to the recruitment of DNA damage-signaling kinases such as ATM and/or ATR and that these kinases then directly signal cell cycle checkpoints and apoptosis (for review, see ref. 2) . In this work, we show that, in addition to MutS␣ activity, exonuclease 1 (Exo1) activity is involved in triggering apoptosis from O 6 MeG DNA lesions. Exo1 plays an important role in eukaryotic MMR and is the only MMR-related exonuclease that has been identified so far (18) (19) (20) (21) (22) (23) (24) (25) . Exo1 may also play a scaffolding role in the assembly of MMR complexes and plays yet other roles in recombination and telomere maintenance (for review, see ref.
2). We find that the absence of Exo1 activity diminishes, and in some tissues completely eliminates, O 6 MeGinduced apoptosis, suggesting that MMR-related excision and resynthesis, and/or some other Exo1 function, is involved in apoptosis induction in response to carcinogenic and chemotherapeutic alkylating agents. (11) , and our goals were to determine whether impairment of the excision step of MMR in Mgmt/Exo1-double null cells would relieve MNNG hypersensitivity and to compare the extent of relief with that observed when mismatch recognition is inactivated in Mgmt/Msh6-double null cells. Fig. 1A shows that the lack of active Exo1 in the Mgmt-null background (Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ MEFs) completely suppressed MNNG hypersensitivity; this was true for two independent MEF isolates. Not surprisingly, the elimination of the MutS␣ mismatch recognition complex in the Mgmt-null background (Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ MEFs) also completely suppressed MNNG hypersensitivity. It should be noted that the MNNG sensitivity of Exo1-and Msh6-single null MEFs is not significantly different from wild type and that the sensitivity of all of the MEF genotypes showed no significant differences upon exposure to a control DNA-damaging agent, UV, whose damage is not subject to Mgmt or MMR (Fig. 1B) . We infer that in the case of primary MEFs, Exo1 function is absolutely required for O 6 MeG-induced cell death, and we thus went on to test several other mouse tissues.
Results

Mgmt
Mgmt ؊/؊ Exo1 ؊/؊ BM, Tested ex Vivo, Is Resistant to SN1-Alkylating Agents. Mgmt-null mouse BM, compared with wild-type BM, is extremely sensitive to S N 1 chemotherapeutic alkylating agents (10) (11) (12) . We have tested BM cells sensitivity to MNU, MNNG, and a control agent mitomycin C (MMC). Fig. 1C (Fig. 1D ). Taking these results together, we infer that as for MEFs, Exo1 function is required for O 6 MeGinduced cell death, presumably by apoptosis.
Elimination of Exo1 or MutS␣ Confers Resistance to Alkylation-
Induced Whole-Animal Lethality. Having shown in two Mgmt-null cell types that a deficiency in Exo1 exonuclease activity confers just as much alkylation resistance as elimination of the mismatch recognition step, we went on to test whether this is also true for whole-animal lethality. Previous studies had shown that elimination of MutL␣ by knocking out Mlh1 in Mgmt-null mice renders those mice just as alkylation-resistant as wild type (13) (Fig. 2A) . The median survival of the MNU-treated Mgmt Ϫ/Ϫ was 10 days after injection vs. 19.5 days for Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ , and for both strains the probable cause of death was neutropenia followed by bacterial sepsis. In a parallel experiment with similarly treated animals that were killed at 8 days for tissue analysis, the BM cellularity of Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ animals was much less depleted compared with Mgmt Ϫ/Ϫ BM, and a typical example is shown in Fig. 2B . At 8 days after treatment, the Mgmt-null BM was depleted by Ϸ95%, whereas the Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ BM was only depleted by Ϸ50%, probably accounting for the fact that Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ mice can survive this MNU dose longer than Mgmt Ϫ/Ϫ mice ( Fig. 2 A) . At this dose of MNU, the BM of wild-type and Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ mice, 8 days after treatment, appears completely healthy (Fig. 2B ). Taken together, these results are only in partial agreement with the ex vivo BM sensitivity assays presented in that the common myeloid progenitor (CMP) lineage is present in the young C57BL/6J bone marrow at the level of 0.2% (26) . Of these CMP, 90% are able to divide and differentiate in methylcellulose to form GM-and MegE-type colonies from the GMP and MEP lineages, respectively (26) . Exo1 function could also possibly play a greater or lesser role in signaling cell death depending on the particular tissue and presumably depending on the different cell types within that tissue.
With regard to other lymphoid tissues of Mgmt Ϫ/Ϫ and Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ mice treated at 30 mg/kg MNU, the thymus was ablated in both genotypes, and splenic red pulp was significantly destroyed in both genotypes, although less so in Mgmt
(data not shown); these tissues were unaffected in all of the other mouse strains. We gleaned from these results and from the rapid death of the sensitive strains (Fig. 2 A) that perhaps the high MNU dose (30 mg/kg) was obscuring differences in alkylation sensitivity of the type seen in the in vitro experiments shown in Fig. 1 . All subsequent in vivo exposures of mice were at a much lower MNU dose (4 mg/kg), whereupon the rescue of Mgmt-null tissues from alkylation sensitivity in the absence of Exo1 activity became much more evident. animals) or with vehicle alone. The ability of this relatively low dose of MNU to induce thymic atrophy at 8 days after treatment is shown for 4 individual mice in Fig. 3A . As shown, albeit at higher doses (13) where wild-type mice do not suffer any thymic atrophy, the Mgmtnull organ is severely shrunken, and cellularity is reduced by Ϸ99%. In stark contrast, the Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ thymus does not appear shrunken and has only incurred very minor histopathological damage. Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ thymus appears just as resistant as the wild-type thymus.
Whereas Fig. 3A presents results from an individual animal for each genotype, Fig. 3B presents results from 11-15 animals for each genotype, at 2 and 8 days after treatment. Wild-type animals suffered minor thymic atrophy at 2 days that was fully resolved by 8 days, but no such recovery was seen in Mgmt-null animals such that by 8 days only small remnants of the thymus were present in all 15 animals. At 8 days after treatment, the absence of Exo1 activity in the Mgmt-null background conferred significant alkylation resistance (P Ͻ 0.0001), but not quite as much as that conferred by elimination of Msh6 (P Ͻ 0.0001) (Fig. 3 A and B) . The difference between the Mgmt/Exo1-and Mgmt/Msh6-double null animals was statistically significant 8 days after MNU administration (P Ͻ 0.0005). The Exo1-and Msh6-single null animal response was similar to wild type (data not shown).
Atrophy Compared with That in Mgmt ؊/؊ Animals. The trend that was seen for the alkylation sensitivity of thymus tissue in the various mutant mouse strains was also observed for the spleen (Fig. 4) . Fig.  4A presents results from an individual animal for each genotype; Mgmt-null was the only strain to display gross atrophy of the spleen, whereas the Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ and Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ spleens appear to be just as resistant as wild type at 8 days after exposure to 4 mg/kg MNU. Overall, the damage observed in Mgmt Ϫ/Ϫ spleens was more extensive than that observed in Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ spleens. The red pulp, consisting mainly of erythrocytes, was almost completely destroyed in the Mgmt Ϫ/Ϫ spleen, whereas in the Mgmt
Exo1
Ϫ/Ϫ spleen the damage was only approximately half that seen in Mgmt Ϫ/Ϫ . The white pulp, consisting almost entirely of mature lymphocytes, was less affected than the red pulp, but again the damage observed in the Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ spleen was approximately half that seen in Mgmt Ϫ/Ϫ . The Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ spleen appears to be just as resistant as the wild-type spleen (Fig. 4A) . In fact, the posttreatment spleen weight for the Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ genotype is not significantly different from Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ . These data are elaborated in Fig. 4B with 11-15 animals per genotype at 2 and 8 days after treatment; the trends are the same as those shown for thymus. The Exo1-and Msh6-single null animal response was similar to wild type (data not shown). Finally, we show that the ablation of BM in animals exposed to the lower 4 mg/kg MNU dose follows the same trend as seen for the thymus and spleen in the same animals. Two days after treatment, BM from all genotypes appeared normal. But, by 8 days after treatment the Mgmt-null BM was reduced by Ϸ90%, whereas that of Mgmt Ϫ/Ϫ Exo1 Ϫ/Ϫ was reduced by only Ϸ50% (Fig. S2) . This was the case seen before in Fig. 2B , but using a much higher dose of MNU. Upon 4 mg/kg treatment, the Mgmt Ϫ/Ϫ Msh6 Ϫ/Ϫ BM is again just as resistant as wild-type BM. We therefore note a partial rescue upon deletion of Exo1 in BM, as in the case of the other lymphoid tissues.
Discussion
In this work, we demonstrate that the murine Exo1 5Ј to 3Ј exonuclease plays a significant role in promoting cell death in tissues containing unrepaired O 6 MeG DNA lesions, lesions that can be induced by a number of known carcinogens and by commonly used cancer chemotherapy drugs. We show that a large fraction (and sometimes all) of the O 6 MeG-induced cell death depends on Exo1 activity. The promotion of O 6 MeG-induced cell death by Exo1 parallels that seen by the MutS␣- (Figs. 1-4) and MutL␣-(13) mediated mismatch recognition step of the MMR pathway. This suggests that the role of Exo1 in the excision steps of MMR may be responsible for promoting O 6 MeG-induced cell death; however, Exo1 plays a variety of different roles in managing DNA damage, and these will be discussed below.
Our data reveal varying responses to O 6 MeG in different primary mouse tissues of Mgmt/Exo1-double null mice compared with either Mgmt-null or Mgmt/Msh6-double null mice. The absence of Exo1 activity led to diminished O 6 MeG-induced cell death in Mgmt/Exo1-double null mice for each tissue tested; however, for some tissues the rescue from death was only approximately half of that seen in Mgmt/Msh6-double null mice, which was virtually complete in all tissues tested. To summarize, the absence of MutS␣ mismatch recognition abolished virtually all O 6 MeG-induced cell death in MEFs, BM-derived myeloid cell progenitors, thymus, spleen, and whole BM; whereas the absence of Exo1 abolished virtually all O 6 MeG-induced cell death in MEFs and BM-derived myeloid cell progenitors, but only partially abolished O 6 MeG-induced cell death in the thymus, spleen, and whole BM. Thus, it seems that the degree of methylation tolerance provided by Exo1 loss is significantly different from loss of Msh6 when toxicity is analyzed in vivo but not ex vivo or with cells in culture.
Characterization of Exo1 function in both yeast and mammals demonstrates several features that are relevant to the interpretation of the results presented here. First, it is quite clear that Exo1-independent mode(s) of excision must contribute to DNA MMR because mutants lacking Exo1 are only partially MMR-deficient, as monitored by less profound increases in spontaneous mutation, microsatellite instability (MSI) and cancer susceptibility (relative to wild type) vs. the larger increases seen in MutS␣-and MutL␣-deficient strains (23, 27) . For multicellular organisms, the contribution of this Exo1-independent excision may vary from tissue to tissue. Indeed, Exo1 mRNA levels vary tremendously between tissues in both mice and humans, with spleen, thymus, and BM showing high levels of expression compared with most other tissues, except the testes (28) . Given the existence of Exo1-independent mode(s) of excision, it is, in fact, rather surprising that any cells from the Exo1-deficient mouse should display an alkylation-resistant phenotype equivalent to those from the MutS␣-deficient mouse, but this was indeed the case for both MEFs and BM-derived myeloid progenitor cells. It is possible that in these cells Exo1 is exclusively participating in MMR. It would be interesting to determine whether Exo1-deficient MEFs and BM-derived myeloid cells display more robust increases in spontaneous mutation and MSI compared with the modest increases monitored in Exo1-deficient ES cells and tail tissue, respectively (23) .
In addition to playing a role in the excision step of MMR, Exo1 plays a variety of other roles for maintaining genome stability, including roles in DNA recombination, DNA replication, and the maintenance of telomeres (29, 30) . In yeast, Exo1 (yExo1) was recently shown to possess two separate domains, one involved in the . P values denote statistically significant differences between mean thymus weights.
excision step of MMR and another that is MMR-independent and is involved in DNA recombination and the restart of stalled replication forks (22) . Additionally, yExo1 was shown to stabilize the MMR complex (31, 32) , demonstrating a potential role of Exo1 as a scaffolding protein for assembly of a MMR complex, at least in yeast (29) . It is possible that the absence of any one, or even all, of these Exo1-related functions in mouse tissues contributes to the diminished promotion of O 6 MeG-induced cell death in Mgmt/Exo1-double null animals. Thus, the tissue-specific differences in the Exo1 requirement for promoting alkylation sensitivity could be because Exo1 plays different roles in different cell types, or as mentioned above, because of differences in redundant exonucleases that can substitute for one or more of the processes in which Exo1 participates. It was recently shown that MutL␣ possesses a latent endonuclease function that is stimulated by mismatch-bound MutS␣ to act as endonuclease for mammalian MMR (33) ; such nicking generates a DNA fragment spanning the mismatch that is then subject to Exo1 degradation; Exo1-mediated degradation is also stimulated by MutS␣ until the mismatch disappears (34) . Mgmt/Exo1-double null mice have intact MutL␣ proteins, and so upon recognition of the O 6 MeG-containing base pair by MutS␣, MutL␣ could in principle create a nick that will ultimately serve to signal apoptosis via a double-stranded DNA break generated at the next round of replication. Thus, the generation of such breaks could happen even in the absence of futile rounds of Exo1-mediated excision. It is therefore possible that in the Mgmt/Exo1-double null tissues rendered only partially resistant to O 6 MeG-induced apoptosis, the residual apoptosis is signaled via MutL␣ endonucleolytic function but that such signaling is amplified when Exo1 is present. Alternatively, in the absence of the putative scaffolding function of Exo1, MutL␣ endonucleolytic function may be compromised in the partially resistant tissues and wholly compromised in the fully resistant tissues. A recent report did indeed show that the endonucleolytic activity of PMS2, one of the members of the MutL␣ complex, is essential for the sensitivity of MEFs to 6-thioguanine, a base that when present in DNA induces cell death in the same MMR-dependent way as O 6 MeG (35). However, we found that for MEFs the absence of Exo1 renders cells just as alkylation-resistant as wild-type cells, and in addition, another recent report showed that Exo1-deficient mouse ES cells are 6-thioguanine-resistant (30) . Taken together, all of these results suggest that both MutL␣-mediated nicking and one or more Exo1 functions are required for triggering cell death in these cells. Exo1 mutants that dissociate its many functions, in particular its scaffolding vs. exonuclease functions, could determine exactly what role(s) Exo1 plays in apoptosis induction in response to O 6 MeG.
It was shown that missense mutations can uncouple Msh2 and Msh6 MMR function from their apoptosis-inducing function (36, 37) . MutS␣ containing either of these mutant subunits can still bind to G:T mismatches, but they do not properly respond to the presence of ATP and do not properly support the completion of MMR; however, these mutants still support apoptotic induction. These results were interpreted to indicate that induction of apoptosis does not require the downstream steps of MMR beyond mismatch recognition. However, since the discovery that mismatchbound MutS␣ stimulates MutL␣-mediated strand nicking (33) excision repair, translesion DNA synthesis, and homologous recombination (38) (39) (40) (41) (42) (43) (44) . The cellular response also involves at least two distinct pathways propagated by the ATM and ATR kinases that respond to DNA double-and single-strand breaks, respectively (45-48); both kinases can be activated in response to unrepaired O 6 MeG lesions in both a MMR-dependent and MMR-independent fashion, albeit with different kinetics after treatment (45, 47) . Our study clearly incorporates Exo1 function as an important modulator of the mammalian cellular response to carcinogenic and chemotherapeutic agents that induce O 6 MeG DNA lesions.
Methods
Reagents. MNNG, MNU, and MMC were from Sigma. Cell culture reagents were purchased from Invitrogen. MethoCult GF was obtained from Stem Cell Technologies. Mgmt, Exo1, and Msh6 genotyping was performed as described (11, 23, 49) .
Mouse Strains. All mouse lines were on a C57BL/6J background and have been described (11, 23, 49) . Mice were fed standard diet ad libitum and housed in an AAALAC accredited facility. Animals were killed by CO 2 asphyxiation, and animal procedures were approved by the MIT Committee on Animal Care.
Growth Inhibition of MEFs by DNA-Damaging Agents.
Early-passage MEFs were treated with varying doses of MNNG in serum-free medium for 1 h and 72 h. After treatment, the extent of growth inhibition was assayed with WST-1 cell proliferation reagent (Roche) according to the manufacturer's instructions. For UV treatment, growth inhibition was tested 48 h after treatment. Three or more separate experiments were performed, and the SEM is presented.
Ex Vivo Bone Marrow Killing Curves. BM cells from femurs of 6-to 11-week-old mice were harvested and treated as described in ref. 11 . Cells were exposed to varying doses of MNU or MMC. Experiments were performed in triplicate.
MNU Treatments of Mice and Subsequent Histopathological Analysis.
Six-to 8-week-old mice were injected i.p. with 4 mg/kg MNU. Two or eight days after injection, the mice were weighed and killed, and the organs were collected. Thymuses and spleens were dissected, photographed, weighed and fixed in 10% buffered formalin (Sigma); femurs were fixed in Bouin's fixative (Sigma). Tissues were examined after H&E staining.
TUNEL Assay. The TUNEL assay is described in SI Methods.
Thirty-Day Drug Toxicity Studies. Six-to 11-week-old mice were injected i.p. with 30 mg/kg MNU. Injected mice were monitored daily, and moribund mice were killed. Thirty days after injection, all surviving mice were killed and tissues fixed in Bouin's fixative. H&E-stained slides of all tissues were prepared and blindly examined by a pathologist (R.T.B.).
Statistical Analysis. Analysis of survival data was done by using linear regression to calculate the IC 50 dose. The Kaplan-Meier plots for the 30-day survival assays after MNU administration were compared by using a log rank test (in GraphPad Prism). GraphPad Prism was also used to determine statistical significance between the mean weights of treated thymuses and spleens. Datasets between the relevant genotypes were compared with an unpaired Student's t test.
